Unsere Arbeitsgruppe beschäftigt sich mit Resistenzen und Resistenzmechanismen von gram-negativen Bakterien und medizinisch wichtigen Pilzen.

Resistenzen gegenüber Antibiotika und Antimykotika haben in den letzten Jahren dramatisch zugenommen. Dies ist u.a. bedingt durch den zu häufigen Einsatz von Antibiotika (Klinik, ambulant, Tierhaltung) und von Antimykotika (Landwirtschaft).

Unsere Arbeitsgruppe hat sich zum Ziel gesetzt, resistente Stämme nachzuweisen und zu charakterisieren sowie die zugrundeliegenden Resistenzmechanismen aufzuklären. Unser Hauptinteresse liegt hierbei bei Antibiotikaresistenzen gegenüber Betalaktamen (z.B. durch ESBLs oder Carbapenemasen wie NDM, KPC, OXA-48 u.a.) und Antimykotikaresistenzen bei Aspergillus spp. gegenüber Triazolen.

Research Topic:

Resistance mechanisms in gram-negative bacteria

Detection and resistance of medically important fungi

Resistance mechanisms in gram-negative bacteria

Resistance to antibiotics has dramatically increased in recent years, especially among gram-negative bacteria (e.g., Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa). These bacteria cause life threatening infections (e.g. sepsis, pneumonia) and can be transmitted from patient to patient.

In the last years, we witness an increasing resistance to commonly used beta-lactam antibiotics, especially to extended spectrum cephalosporins. Resistance is commonly caused by extended spectrum beta lactamases that can hydrolyze many beta lactams.

Another threat which is still rare in Germany is the resistance to carbapenems (e.g., ertapenem, meropenem, imipenem), which is caused by carbapenemases such as NDM (New Delhi metallo-beta-lactamase), KPC, VIM, OXA-48 and others.

The main interest of our group is to identify and characterize resistant Gram-negative bacteria and to understand why some species and clones can disseminate successfully.

Furthermore, we work on the rapid detection of carbapenemase-producing Enterobacteriaceae directly from clinical specimen.

Detection and resistance of medically important fungi

With the growing number of immune-compromised patients, we witness an increasing number of infections by opportunistic pathogens, especially fungi. Invasive fungal infections such as aspergillosis show a very high mortality and are particularly difficult to treat. This problem has been aggravated by an increasing resistance to triazole antifungals, the mainstay of aspergillosis therapy. This phenomenon has only been observed in the last years and is likely caused the use of azole fungicides in agriculture.

Our current research focuses on azole resistance in Aspergillus spp. and the detection and resistance of “rare” fungi, such as Fusarium spp.


Dr. Volker Kinast

Dr. Janina Noster

Martina Spille

Yvonne Stelzer

Dr. Gerrit Wienhausen


Aktuelle Publikationen s. Pubmed


Ausgewählte Publikationen

Sattler J, Tsvetkov T, Stelzer Y, Schäfer S, Sommer J, Noster J, Göttig S, Hamprecht A., Emergence of Tn1999.7, a New Transposon in blaOXA-48 Harboring Plasmids Associated with Increased Plasmid Stability. Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0078722. doi: 10.1128/aac.00787-22. Epub 2022 Oct 6. PMID: 36200773; PMCID: PMC9664867.


Noster J, Koeppel MB, Desnos-Olivier M, Aigner M, Bader O, Dichtl K, Göttig, S, Haas A, Kurzai O, Pranada AB, Stelzer Y, Walther G, Hamprecht A. Bloodstream Infections Caused by Magnusiomyces capitatus and Magnusiomyces, Clavatus: Epidemiological, Clinical, and Microbiological Features of Two, Emerging Yeast Species. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0183421. doi: 10.1128/AAC.01834-21. Epub 2021 Dec 20. PMID: 34930027; PMCID: PMC8846490.


Noster J, Thelen P, Hamprecht A. Detection of Multidrug-Resistant, Enterobacterales-From ESBLs to Carbapenemases. Antibiotics (Basel). 2021, Sep 21;10(9):1140. doi: 10.3390/antibiotics10091140. PMID: 34572722; PMCID: PMC8465816.


Fuchs F, Hof H, Hofmann S, Kurzai O, Meis JF, Hamprecht A. Antifungal activity of nitroxoline against Candida auris isolates. Clin Microbiol Infect. 2021 Nov;27(11):1697.e7-1697.e10. doi: 10.1016/j.cmi.2021.06.035. Epub 2021 Jul, 7. PMID: 34245904.


Fuchs F, Ahmadzada A, Plambeck L, Wille T, Hamprecht A. Susceptibility of Clinical Enterobacterales Isolates With Common and Rare Carbapenemases to Mecillinam. Front Microbiol. 2021 Jan 12;11:627267. doi: 10.3389/fmicb.2020.627267. PMID: 33510739; PMCID: PMC7835630.


Sattler J, Noster J, Brunke A, Plum G, Wiegel P, Kurzai O, Meis JF, Hamprecht A. Comparison of Two Commercially Available qPCR Kits for the Detection of Candida auris. J Fungi (Basel). 2021 Feb 22;7(2):154. doi: 10.3390/jof7020154.


Rohde AM, Zweigner J, Wiese-Posselt M, Schwab F, Behnke M, Kola A, Schröder W, Peter S, Tacconelli E, Wille T, Feihl S, Querbach C, Gebhardt F, Gölz H, Schneider C, Mischnik A, Vehreschild MJGT, Seifert H, Kern WV, Gastmeier P, Hamprecht A. Prevalence of third-generation cephalosporin-resistant Enterobacterales colonization on hospital admission and ESBL genotype-specific risk factors: a cross-sectional study in six German university hospitals. J Antimicrob Chemother. 2020 Jun 1;75(6):1631-1638. doi: 10.1093/jac/dkaa052. PMID: 32173738.


Hamprecht A, Sommer J, Willmann M, Brender C, Stelzer Y, Krause FF, Tsvetkov T, Wild F, Riedel-Christ S, Kutschenreuter J, Imirzalioglu C, Gonzaga A, Nübel U, Göttig S. Pathogenicity of Clinical OXA-48 Isolates and Impact of the OXA-48 IncL Plasmid on Virulence and Bacterial Fitness. Front Microbiol. 2019 Nov 1;10:2509. doi: 10.3389/fmicb.2019.02509. PMID: 31736929; PMCID: PMC6838017.


Meier M, Hamprecht A. Systematic Comparison of Four Methods for Detection of Carbapenemase-Producing Enterobacterales Directly from Blood Cultures. J Clin Microbiol. 2019 Oct 23;57(11):e00709-19. doi: 10.1128/JCM.00709-19. PMID: 31413083; PMCID: PMC6813004.


Lucena Baeza L, Pfennigwerth N, Hamprecht A. Rapid and Easy Detection of Carbapenemases in Enterobacterales in the Routine Laboratory Using the New GenePOC Carba/Revogene Carba C Assay. J Clin Microbiol. 2019 Aug 26;57(9):e00597-19. doi: 10.1128/JCM.00597-19. PMID: 31315949; PMCID: PMC6711903.


Fuchs F, Hamprecht A. Susceptibility of carbapenemase-producing Enterobacterales (CPE) to nitroxoline. J Antimicrob Chemother. 2019 Oct 1;74(10):2934-2937. doi: 10.1093/jac/dkz275. PMID: 31292653.


Hamprecht A, Barber AE, Mellinghoff SC, Thelen P, Walther G, Yu Y, Neurgaonkar P, Dandekar T, Cornely OA, Martin R, Kurzai O; German Candida auris Study Group. Candida auris in Germany and Previous Exposure to Foreign Healthcare. Emerg Infect Dis. 2019 Sep;25(9):1763-1765. doi: 10.3201/eid2509.190262. Epub 2019 Sep 17. PMID: 31223105; PMCID: PMC6711216.


Fuchs F, Hamprecht A. Results from a Prospective In Vitro Study on the Mecillinam (Amdinocillin) Susceptibility of Enterobacterales. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02402-18. doi: 10.1128/AAC.02402-18. PMID: 30917983; PMCID: PMC6437539.


Baeza LL, Pfennigwerth N, Greissl C, Göttig S, Saleh A, Stelzer Y, Gatermann SG, Hamprecht A. Comparison of five methods for detection of carbapenemases in Enterobacterales with proposal of a new algorithm. Clin Microbiol Infect. 2019 Oct;25(10):1286.e9-1286.e15. doi: 10.1016/j.cmi.2019.03.003. Epub 2019 Mar 18. PMID: 30898725.


Hamprecht A, Vehreschild JJ, Seifert H, Saleh A. Rapid detection of NDM, KPC and OXA-48 carbapenemases directly from positive blood cultures using a new multiplex immunochromatographic assay. PLoS One. 2018 Sep 14;13(9):e0204157. doi: 10.1371/journal.pone.0204157. PMID: 30216371; PMCID: PMC6138386.


Hamprecht A, Göttig S. Häufigkeit und Vorkommen multiresistenter gramnegativer Erreger: 3MRGN/4MRGN [Prevalence of Multidrug-Resistant Gram-Negative Bacteria]. Dtsch Med Wochenschr. 2018 May;143(9):625-633. German. doi: 10.1055/s-0043-113597. Epub 2018 Apr 23. PMID: 29684929.


Hamprecht A, Morio F, Bader O, Le Pape P, Steinmann J, Dannaoui E. Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern? Mycopathologia. 2018 Feb;183(1):151-160. doi: 10.1007/s11046-017-0162-4. Epub 2017 Jun 26. PMID: 28653258.


Hamprecht A, Rohde AM, Behnke M, Feihl S, Gastmeier P, Gebhardt F, Kern WV, Knobloch JK, Mischnik A, Obermann B, Querbach C, Peter S, Schneider C, Schröder W, Schwab F, Tacconelli E, Wiese-Posselt M, Wille T, Willmann M, Seifert H, Zweigner J; DZIF-ATHOS Study Group. Colonization with third-generation cephalosporin-resistant Enterobacteriaceae on hospital admission: prevalence and risk factors. J Antimicrob Chemother. 2016 Oct;71(10):2957-63. doi: 10.1093/jac/dkw216. Epub 2016 Jun 17. PMID: 27317445.


Göttig S, Riedel-Christ S, Saleh A, Kempf VA, Hamprecht A. Impact of blaNDM-1 on fitness and pathogenicity of Escherichia coli and Klebsiella pneumoniae. Int J Antimicrob Agents. 2016 Jun;47(6):430-5. doi: 10.1016/j.ijantimicag.2016.02.019. Epub 2016 Apr 26. PMID: 27179815.


Steinmann J, Hamprecht A, Vehreschild MJ, Cornely OA, Buchheidt D, Spiess B, Koldehoff M, Buer J, Meis JF, Rath PM. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother. 2015 May;70(5):1522-6. doi: 10.1093/jac/dku566. Epub 2015 Jan 27. PMID: 25630644.


Fischer J, van Koningsbruggen-Rietschel S, Rietschel E, Vehreschild MJ, Wisplinghoff H, Krönke M, Hamprecht A. Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients. J Antimicrob Chemother. 2014 Jun;69(6):1533-6. doi: 10.1093/jac/dku009. Epub 2014 Jan 31. PMID: 24486872.


Hamprecht A, Poirel L, Göttig S, Seifert H, Kaase M, Nordmann P. Detection of the carbapenemase GIM-1 in Enterobacter cloacae in Germany. J Antimicrob Chemother. 2013 Mar;68(3):558-61. doi: 10.1093/jac/dks447. Epub 2012 Nov 14.PMID: 23152484.


Hamprecht A, Buchheidt D, Vehreschild JJ, Cornely OA, Spiess B, Plum G, Halbsguth TV, Kutsch N, Stippel D, Kahl P, Persigehl T, Steinbach A, Bos B, Hallek M, Vehreschild MJ. Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill. 2012 Sep 6;17(36):20262. PMID: 22971327.